Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adding a nicotine blocking agent to cigarette tapering.

Peter Gariti1, Arthur I Alterman, Kevin G Lynch

  • 1Treatment Research Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. gariti_p@mail.trc.upenn.edu

Journal of Substance Abuse Treatment
|June 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three-arm randomised controlled trial of text message reminders and financial incentives to improve antidepressant adherence among adults in primary care with depression: study protocol.

BMJ open·2026
Same author

Adjunctive Psychosocial Interventions and Opioid Abstinence Among Patients Receiving Buprenorphine: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Adiposity and inflammation mediate altered metabolic profile in individuals with opioid use disorder.

Journal of psychiatric research·2026
Same author

Efficacy signals in a 12-week trial of clavulanic acid to decrease cocaine use.

Drug and alcohol dependence·2026
Same author

Adiposity and inflammation mediate altered metabolic profiles in individuals with opioid use disorder.

medRxiv : the preprint server for health sciences·2026
Same author

RAMP-UP: Pharmacist-Led Methadone Titration for Hospitalized Patients With Opioid Use Disorder.

Substance use & addiction journal·2026
Same journal

Call for commentaries on COVID-19.

Journal of substance abuse treatment·2024
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.

Journal of substance abuse treatment·2022
Same journal

Factors associated with the adoption of evidence-based innovations by substance use disorder treatment organizations: A study of HIV testing.

Journal of substance abuse treatment·2022
See all related articles

A novel nicotine-blocking agent (Accu Drop) combined with counseling did not improve smoking cessation rates compared to placebo. Further research is not recommended at this stage.

Area of Science:

  • Addiction Medicine
  • Pharmacology

Background:

  • Smoking cessation remains a significant public health challenge.
  • Nicotine dependence is characterized by high Fagerstrom scores and cotinine levels.
  • Novel non-pharmacologic interventions are needed to aid smoking cessation.

Purpose of the Study:

  • To evaluate the efficacy of a non-pharmacologic nicotine-blocking agent (Accu Drop; AD) combined with brief counseling (C) for smoking cessation.
  • To compare smoking abstinence rates between the Accu Drop plus counseling (AD&C) group and a placebo drop plus counseling (PD&C) group.

Main Methods:

  • A 6-week, randomized, double-blind, placebo-controlled study involving 60 participants.
  • Participants received either Accu Drop or placebo in conjunction with brief counseling.
  • Demographic data, Fagerstrom scores, plasma cotinine levels, and withdrawal symptoms were recorded.

Related Experiment Videos

Main Results:

  • No significant differences were observed between the AD&C and PD&C groups in withdrawal scores or treatment completion rates (55%).
  • Biochemically confirmed smoking abstinence rates at 1 week, 1 month, and 6 months post-treatment did not differ significantly between groups.
  • AD&C group abstinence rates were 10%, 13%, 10% at follow-ups, versus 3%, 10%, 13% for PD&C.

Conclusions:

  • The preliminary findings do not support the efficacy of Accu Drop as an adjunct to brief counseling for smoking cessation.
  • There is insufficient evidence to warrant a Stage II clinical trial for this intervention.